Table 1.

Study inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Adults of 18–70 years of age, who were recipients of first LTs from a deceased donor	Donation after cardiac death
Informed consent from all patients	Living-donor recipients
Additional inclusion criteria	Split liver recipients
Reliable IV access	Recipients of organs
ABO compatible donor-recipient pairs	From donors <12 years or >65 years of age
Patients with hepatocellular carcinoma meeting Milan criteria (one nodule ≤5 cm in diameter or three or fewer nodules, with none >3 cm in diameter)	With anticipated cold ischemia time >14 h
	From donors who were positive for HBV or HCV when recipients were negative for HBV or HCV, respectively
	From donors with known human immunodeficiency virus infection
	Patients receiving dialysis before LT for ≥2 consecutive weeks before enrollment or who were anticipated to have prolonged dialysis posttransplant
	Patients with known intrinsic kidney disease (e.g. a urine protein/creatinine ratio >150 mg/g or presence of an abnormal number of red blood cells or granular casts in urine) AND a calculated GFR (cGFR) <40 mL/min/1.73 m2 body surface area (modified MDRD) within 1 month of enrollment
	Patients with acute liver failure, hypercoagulable state or malignancy within the previous 5 years (except for nonmelanoma skin cancer cured by local resection or hepatocellular carcinoma as defined above)
	Patients who were seronegative for Epstein–Barr virus (subsequent study amendment)

HBV, hepatitis B virus; HCV, hepatitis C virus; IV, intravenous; LT, liver transplant.